A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
Recruiting · NCT07589244 · Registry updated 2026-05-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC | hepatocellular carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-05-15 | NCT07589244 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangzhou Virotech Pharmaceutical Co., Ltd. | 8 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Third Affiliated Hospital of Sun Yat-sen University | Guangzhou | China | 17 |